Deep Intelligence Across Industries

X-FAB is Europe's largest pure-play specialty foundry. It manufactures analog/mixed-signal, high-voltage, SOI, MEMS/microsystems, photonics and wide-bandgap (SiC and GaN) semiconductors on mature 150mm and 200mm lines across six fabs in Germany, France, Malaysia and the United States. It does not compete in the leading-edge node race. Instead, it supplies long-lifecycle technologies, from 1.0µm down to 110nm, with automotive-grade qualification, modular process options and deep design-kit support. Fabless and fab-lite chip companies in automotive, industrial and medical markets use these technologies; those three core markets generated 94% of FY2025 revenue [PR Q4-25]. The company has just completed a roughly USD 1.1bn, three-year capacity programme (2023–25). It is now in a cyclical trough: Q2 2026 EBITDA margin was 16.8%, against a long-term target above 30%. Management is repositioning the portfolio toward three pillars: Smart CMOS & SOI, Microsystems & Photonics, and Wide Bandgap. It is targeting data-centre power and optical connectivity as a new growth vector worth about USD 300m in long-term annual revenue potential [PR Q2-26]. --- ### What the company does X-FAB is a contract manufacturer (foundry) of silicon wafers. Customers design integrated circuits, sensors, MEMS devices or power discretes using X-FAB's process design kits (PDKs) and IP libraries. X-FAB then processes the wafers in its fabs and ships finished, tested wafers to the customer or its assembly partner. The company sells ex-works: delivery occurs at X-FAB's premises, and cost and risk pass to the buyer from that point. Management has stated that tariffs therefore have no direct effect on its operations (KBC/Bolero commentary, Apr 2025). ### Company's own description (paraphrased from latest releases) In its 2026 boilerplate, X-FAB describes itself as a global foundry group offering a broad set of specialty technologies and design IP. These are manufactured in six wafer fabs in Malaysia, Germany, France and the US. Its expertise spans analog/mixed-signal, microsystems, photonics, SiC and GaN, and it acts as development and manufacturing partner mainly to automotive, industrial and medical customers [PR Q2-26]. At the September 2025 Investor Day, the company branded itself as "the European specialty foundry for the analog world" [PR ID-25]. ### Business and revenue model | Revenue element | Description | Share / evidence | |---|---|---| | Wafer production | Volume wafer sales priced per wafer, depending on technology, mask layers and options | ≈90.6% of revenue (ABC Bourse, citing latest annual report) | | Prototyping / engineering services | Multi-project wafer (MPW) runs, engineering lots, NRE and customer-specific process development | ≈9.4% of revenue (same source). Prototyping revenue was USD 108.8m in FY2023 [PR Q4-23] and USD 17.7m in Q2 2026 [PR Q2-26] | | Long-term agreements (LTAs) | Capacity-reservation contracts, partly with customer prepayments | Seven LTAs worth USD 1.4bn over three years covered a large part of 200mm CMOS capacity (Feb 2023) [PR Q4-22] | | Licensing / subscriptions | Not a material separate revenue line | Not publicly disclosed as separate revenue | Revenue is recognised partly over time under IFRS 15. This creates quarterly "impact from revenue recognised over time" adjustments, ranging from −10.3m in Q1 2026 to +4.2m in Q4 2025. Currency mix in FY2025 was 57% USD and 43% EUR. The company describes its business as naturally hedged at EBITDA level [PR Q4-25]. ### Value-chain position X-FAB sits between fabless/fab-lite designers (upstream) and OSAT/module makers (downstream). Raw materials are silicon wafers, SiC substrates (partly customer-consigned), gases and chemicals. Its differentiation comes from four sources: 1. **Mature-node specialty process breadth.** These include high-voltage, SOI, embedded NVM, optical sensors and MEMS. 2. **Automotive-grade quality and long product life.** Customers can rely on processes being supported for many years. 3. **Multi-site process duplication.** For example, 180nm is run in France and Malaysia for business continuity. 4. **Design ecosystem tools.** These include FeatureXplorer, ResourceXplorer, X-CHAIN and the IP Portal. ### Customer types and end-markets | End-market | FY2025 Revenue* (USD m) | Share of Revenue* | Key applications cited | |---|---|---|---| | Automotive | 558.3 | 64.3% | Battery and thermal management, on-board chargers, ADAS, next-generation headlamps | | Industrial | 184.6 | 21.3% | SiC power for renewables/UPS, last-time-buy legacy CMOS, photonics prototyping | | Medical | 71.3 | 8.2% | DNA sequencing, ultrasound/echography, contactless temperature sensors, pacemakers | | CCC (Consumer, Communications & Computer) | 52.7 | 6.1% | Legacy consumer and communications ICs (declining by design) | | Others | 0.9 | 0.1% | — | Customers are fabless semiconductor firms, IDMs outsourcing specialty steps, and system companies developing ASICs. Melexis NV is a historically important customer and related party; the same founding families are its shareholders. Source: [PR Q4-25] quarterly tables, summed by analyst. ### Independent characterisation X-FAB is a capital-intensive, mid-cycle analog foundry with very high operating leverage. Its cost base is about 75–85% fixed (depreciation plus staff). As a result, a 10% revenue swing has moved the EBITDA margin by 5–10 percentage points, as seen between 2023 and 2024. Its strategic value lies in four areas: - European sovereignty in mature-node supply, reflected in the EUR 127.4m Chips Act grant. - Automotive qualification moats. - Unusual technology adjacency (CMOS plus MEMS plus SiC/GaN plus photonics under one roof). - A cost-competitive Malaysian 200mm site. Its structural weaknesses are: - Concentration in automotive. - No 300mm footprint, a point raised by Deutsche Bank in November 2025. - Exposure to Chinese mature-node overcapacity. - A thin free float controlled by founding families and the Sarawak state.

Company Headquarters: Taiwan Founded: 1984 Workforce: ~65,695 Company Working: ASE Technology Holding Co., Ltd. mainly engages in the general investment business. The company provides customers with three types of services. Integrated Circuit (IC) services include packaging and module design, IC packaging, and multi-chip packaging; testing services, including previous testing, wafer pin testing, and finished product testing, as well as materials, including substrate design and manufacturing. Electronic manufacturing service businesses are involved in the development and design of communication, consumer electronics, computers, storage, industrial, automotive electronics, and other types of electronic products, the material procurement business, logistics, maintenance, and other after-sales services. Other services include real estate development, construction, home sales property management, and shopping mall rental business. The company distributes its products to the US, Taiwan, Europe, Asia, and other regions.

Company Headquarters: Reggio Emilia Founded: 1960 Workforce: ~40,000 Company Working: Dana Motion Systems manufactures hydraulic – electronic components and a complete mechanical transmission range able to fit the needs of mobile and stationary applications in terms of working functions. The company creates and manufactures a full variety of mechanical transmissions, hydraulic, and electrical components that meet the needs of numerous industries, by merging various technologies. The company, a lone provider of comprehensive tailored systems, tops the industry in terms of client satisfaction due to its diverse product offering, regional reach, personalized solutions, and unparalleled knowledge. The Dana Motion Systems has production units in Europe and China, and a wide direct presence all over the world with its service and assembly centers, ensuring the highest closeness to the customer.

Company Headquarters: Mannheim, Germany Founded: 1931 Workforce: ~5,976 Company Working: Fuchs Petrolub SE (Fuchs) is an independent lubricant manufacturer that develops, produces, and commercializes lubricants and related specialties worldwide. Automotive lubricants, industrial lubricants, metal-working fluids, and lubricants for specialized purposes are among the company's product offerings. A wide number of industries are served by Fuchs, including agricultural, automotive, mining and exploration, metalworking, agriculture and forestry, aerospace, power generation, mechanical engineering, construction, transport, steel, metal and cement, food, glass production, and casting and forging. It also provides services that are technical, and process related. The business has operations throughout Asia-Pacific, Europe, North America, South America, and the Middle East.

TotalEnergies is Europe's largest integrated energy company by market value and the most transition-tilted of the five Western supermajors. It produces roughly 2.5 Mboe/d of oil and gas (2,529 kboe/d in FY2025 [V]), runs the world's third-largest LNG portfolio by sales volume (43.9 Mt sold in FY2025 [V]), and has built a sizeable electricity business (48.1 TWh net generation in FY2025, 26.0 GW net installed capacity [V]) that it targets at 100–120 TWh by 2030. Its strategic identity rests on two pillars — Oil & Gas (with an LNG emphasis) and Integrated Power — financed by low-cost upstream barrels (operating cost ~$5/boe [V]) and a disciplined capital framework (net investments $14–17 bn/yr for 2027–2032 [V]). It has posted the highest ROACE among the majors for four consecutive years (12.6% in FY2025 [V]), returns at least 40% of cash flow to shareholders, and in September 2026 committed to growing its dividend by more than 5% a year through 2030 [V]. --- **Company's own description.** In its standard corporate boilerplate (2026), TotalEnergies describes itself as a global integrated energy company that produces and markets oil and biofuels, natural gas, biogas and low-carbon hydrogen, renewables and electricity, with more than 100,000 employees, active in about 120 countries, and placing sustainability at the heart of its strategy, projects and operations [V — paraphrased from the 2026 press-release boilerplate]. **Business model.** TotalEnergies is a vertically integrated commodity producer, processor, trader and marketer. Value is generated at five points of the chain, which correspond to its five reporting segments: 1. **Exploration & Production (E&P)** — finds, develops and produces crude oil, NGLs and pipeline gas under concessions, production-sharing contracts and joint ventures. Revenue is commodity-price-linked; margins depend on Brent, realised gas prices, fiscal terms and unit costs. FY2025 E&P adjusted net operating income (ANOI) $8,399 M on capital employed of $65.1 bn (ROACE 13.0%) [V]. 2. **Integrated LNG** — upstream gas dedicated to liquefaction, equity stakes in liquefaction plants, LNG shipping, regasification capacity, and a large LNG and gas trading book (third-party purchases plus equity volumes). FY2025 ANOI $4,109 M [V]. 3. **Integrated Power** — renewable (solar, onshore and offshore wind, hydro) and flexible gas-fired generation, battery storage, power and gas trading, and retail/B2B supply of electricity and gas (6.0 M power clients, 2.7 M gas clients at end-2025 [V]). Its model involves developing projects, farming down 50% stakes to recycle capital ("renewables business model"), and integrating production with customer offtake. FY2025 ANOI $2,215 M; CFFO $2.6 bn, split 55% production / 45% marketing [V]. 4. **Refining & Chemicals (R&C)** — refining (1,526 kb/d throughput in FY2025 [V]), petrochemicals (monomers 4,967 kt and polymers 4,658 kt in FY2025 [V]), biofuels and oil trading. FY2025 ANOI $2,378 M; ROACE 37.8% on a replacement-cost basis [V]. 5. **Marketing & Services (M&S)** — retail fuel networks, lubricants, aviation and marine fuels, bitumen, LPG, EV charging and B2B fuel cards; 1,276 kb/d of petroleum products sold in FY2025 [V]. FY2025 ANOI $1,373 M; ROACE 20.0% [V]. **Revenue model mix.** TotalEnergies does not report a product/service/subscription/licensing split. On an analyst characterisation, essentially all revenue is product (commodity) sales; services revenue (e.g., EV charging, fuel cards, lubricant services) is immaterial and undisclosed; licensing and subscription revenue are negligible. Contracted or quasi-regulated revenue exists in Integrated Power (PPAs, tolling agreements; e.g., ~40% of EPH-JV gross margin described by the company as secured [V — Nov 2025 EPH presentation]) and in long-term LNG sale and purchase agreements. **Value-chain position.** Full-spectrum: upstream resource holder → midstream (LNG liquefaction, shipping, regas) → downstream (refining, petrochemicals) → end-customer marketing (retail fuel, power, gas). Trading (crude, products, LNG, gas, power) sits across segments and is a material, if undisclosed, contributor to earnings volatility (e.g., Q1 2026 LNG trading outperformance; Q2 2026 gas-trading underperformance [V]). **Customer types.** National oil companies and utilities (LNG, gas), refiners and traders (crude), industrial and commercial B2B customers (power PPAs — e.g., Google, Airbus, Data4 [V]; gas; lubricants; polymers), transport and aviation fleets (jet fuel, SAF, marine fuels, truck networks), and retail consumers (service stations; residential power and gas, chiefly in France and Belgium). **End-markets.** Global oil market; global LNG (Asia and Europe principal sinks); European and US wholesale power; European retail power and gas; European and Middle East/Asia petrochemicals; road, aviation and marine fuels in Europe and Africa. **Independent characterisation.** TotalEnergies is best understood as an oil-and-LNG cash engine (E&P + LNG generated $20.3 bn of FY2025 CFFO, ~73% of the total [V, computed]) funding a build-out of a utility-like power business whose returns (ROACE 9.7% in FY2025 [V]) remain below the upstream's but are guided to reach 12% by 2030 [V]. The company differs from US peers in the scale of its power ambitions and from BP/Shell in the consistency with which it has held its transition strategy while protecting upstream growth.

Company Headquarters: Nevada, US Founded: 2010 Workforce: ~100 Company Working: CV Sciences, Inc. is a manufacturer of safe, high-quality, and effective CBD oil products. The company is focusing on promoting healthy living through its pharmaceutical drug development efforts and portfolio of finished product brands. It is the maker of PlusCBD Oil, the leading brand in hemp-derived CBD oil products available online, in health food stores, and in practitioners' offices in the US. The company operates two business segments, including a consumer product division and a drug development division. Its drug development division involves developing and commercializing CBD-based novel therapeutics utilizing CBD, and its consumer product division involves manufacturing, marketing, and selling plant-based CBD products.

Company Headquarters: Ontario, Canada Founded: 2013 Workforce: ~2,100 Company Working: Aphria Inc. is a Canada-based company that provides safe, clean, and pure pharmaceutical-grade cannabis to its customers. The company runs its business through retail and wholesale channels both domestically and internationally. In addition to operating in more than 10 other countries besides Canada, Aphria is a significant supplier of medical cannabis to Germany. Moreover, the company operates as a subsidiary of Tilray, Inc (US) which was acquired in December 2020. It also focuses on the research and development of innovative products and spends a significant amount of revenue on R&D Furthermore, the company is directly present in more than ten countries and has a strong presence in all the established markets such as North America, Europe, Africa, and Australia

Company Headquarters: United States Founded: 1862 Workforce: ~ 27,043 (Global) Company Working: NOV Inc. (NOV or 'the company'), formerly, National OilWell Varco Inc, is a provider of technology and equipment to the oil and gas industry. The company conducts operations in approximately 552 locations across six continents. It owns and leases 137 engineering, sales and administration facilities, 109 service centers and 306 repair and manufacturing facilities. The company serves national and independent service companies, oil and gas operators and contractors in 61 countries worldwide. NOV operates its business through three reportable business segments: Rig Technologies, Wellbore Technologies, and Completion and Production Solutions. The Rig Technologies segment supports the integrated systems and capital equipment, which are used to drill oil and gas wells on land and offshore. It also designs, manufactures and sells land rigs, offshore drilling equipment packages, such as installation and commissioning services, and drilling rig components which mechanize and automate the drilling process and rig functionality. NOV's rig system segment's equipment and technologies include derricks, substructures, and masts; jacking systems; cranes; rotating, and assembly systems, pipe lifting, racking; fluid transfer technologies, such as mud pumps; power transmission systems, including drives and generators; and rig instrumentation and control systems; pressure control equipment, including blowout preventers. It operates manufacturing facilities in New Iberia, Louisiana; Orange, California; Houston, Texas; Dubai, UAE; and Singapore. As of December 2021, it had order backlog of US$2.8 billion. In FY2021, the Rig Technologies segment reported revenue of US$1,739 million, which accounted for 30.7% of the company’s revenue. NOV's Wellbore Technologies segment designs, manufactures, sells and rents various equipment and technologies used for drilling operations. It also offers services that optimize their performance, including solids control and waste management equipment and services, drill pipe, wired pipe, tubular repair, inspection and coating services, fishing and downhole tools, instrumentation and drill bits. The segment serves oil and gas companies and supports oilfield equipment rental companies, drilling contractors and oilfield service companies. It operates manufacturing facilities in Veracruz, Mexico; Houston, Navasota, Conroe, and Cedar Park, Texas; and Dubai, UAE. In FY2021, the Wellbore Technologies segment reported revenue of US$1,959 million, which accounted for 34.6% of the company’s revenue. The Completion and Production Solutions segment integrates technologies for oil and gas production and well completions. It designs, manufactures, and sells equipment and technologies needed for hydraulic fracture stimulation, including pressure pumping trucks, sanders, blenders, hydration units, flow line, manifolds, and injection units. It also manufactures well intervention products, including coiled tubing, coiled tubing units and wireline units and tools; and onshore production systems, including surface transfer, composite pipe, and progressive cavity pumps, and artificial lift systems. In addition, the company supplies offshore production systems, including floating production systems and subsea production technologies. The segment also supports oil and gas companies and service companies. It operates manufacturing facilities in Tulsa, Oklahoma; Houston, and Fort Worth, Texas; Qingdau, Shandong, China; Aberdeenshire, Scotland, UK; Senai, Malaysia; Kalundborg, Denmark; Manchester, England; and Superporto du Acu, Brazil. As of December 2021, it had order backlog of US$1.3 billion. In FY2021, the Completion and Production Solutions segment reported revenue of US$1,963 million, which accounted for 34.7% of the company’s revenue. Geographically, the company classifies its operations into 11 regions: the US, Norway, Singapore, Saudi Arabia, the UK, China, Brazil, Canada, the UAE, South Korea, and Other Countries. In FY2021, the US accounted for 31.9% of the company’s revenue, followed by Norway (6.6%), Singapore (2.6%), Saudi Arabia (5.7%), the UK (3.7%), China (4%), Brazil (5.7%), Canada (3.7%), the UAE (2.4%), South Korea (0.6%), and Other Countries (33.1%).

Company Headquarters: US Founded: 1989 Workforce: 4,700 Company Working: Integra Life Sciences is a leading global medical technology company that specializes in developing, manufacturing, and marketing innovative products and solutions to meet the needs of surgeons, healthcare professionals, and patients worldwide. Integra products are sold in over 130 countries via a direct sales force, distributors, and wholesalers. Codman Specialty Surgical ("CSS") and Tissue Technologies ("TT") are the two reportable business segments in which company manufacture and sell medical technologies and products. The CSS segment, which accounts for two-thirds of our total revenue, consists of market-leading technologies and instrumentation used in a variety of specialties, including neurosurgery, neurocritical care, and otolaryngology.

Company Headquarters: US Founded: 1897 Workforce: 77,000 Company Working: BD (Becton, Dickinson and Company) is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is a leading global medical technology company that is committed to advancing the world of health. The company operates in three main segments: BD Medical, BD Life Sciences, and BD Interventional. Its products and services are used in a wide range of medical settings, including hospitals, clinics, and research laboratories. BD's product portfolio includes a wide range of medical devices and instrument systems, including syringes, needles, catheters, diagnostic tests, and imaging systems. The company is also a leader in the development of healthcare software and data analytics solutions. BD's breast biopsy products are designed to improve the accuracy, speed, and safety of breast biopsy procedures, ultimately leading to better patient outcomes. BD has a significant global presence, with operations in over 190 countries around the world.

Company Headquarters: Basel, Switzerland Founded: 1966 Workforce: ~108,000 Company Working: Novartis International AG (Novartis) is engaged in the production of pharmaceutical drugs. It is a fully integrated life sciences company that provides research, product development, manufacturing, and distribution of products. It is an outstanding worldwide source of regenerative medicine technology, clinical research, education, and training for the constantly evolving healthcare industry. It ranks among the world’s top companies investing in research and development. It carries out research at Novartis locations and partner institutions worldwide: Cambridge, the US; Basel, Switzerland; East Hanover, US; Emeryville, US; and Shanghai, China. Sandoz, a Novartis division, is a global provider of generic pharmaceuticals and biosimilars.

Company Headquarters: Beijing, China Founded: 2015 Workforce: ~300 Company Working: Jacobio Pharmaceuticals Group Co., Ltd. is a biotechnology company that develops and sells autoimmune drugs, cancer drugs, infectious disease drugs, and other products. It has R&D centers in Shanghai, China, and the US. The company manufactures and markets its products throughout China. It is also making partnerships with other players for R&D programs to develop innovative medicines.

Company Headquarters: Washington, US Founded: 1997 Workforce: ~ 2,700 Company Working: Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. It offers antibody-drug conjugates (ADCs), including Padcevtm (enfortumab vedotin-ejfv), which is used to treat metastatic urothelial cancers, Adcetris (brentuximab vedotin), which is used to treat Hodgkin's lymphoma, T-cell lymphomas, and CD30-expressing lymphomas. (Tucat) Tukysa. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Additionally, Seagen also licenses its antibody-drug conjugate technology to several biotechnology and pharmaceutical companies. Seagen serves customers on a global scale.

Company Headquarters: New York, US Founded: 1959 Workforce: ~254 Company Working: Misonix, Inc. specializes in the development and commercialization of ultrasonic surgical devices for spinal, neurosurgical, advanced wound care, and general surgery procedures. The company's products enhance clinical outcomes and benefit the entire healthcare system. In addition, the company derives revenue from a number of locations, including the US, the UK, the European Economic Area, Asia and the Asia Pacific, and South America. The company operates in more than 45 countries and is a recognized leader in advanced surgical tools offering unprecedented safety, speed, and precision.

Company Headquarters: New York, US Founded: 1988 Workforce: ~1,200 Company Working: AngioDynamics manufactures disruptive and innovative medical devices. The company provides vital tools to healthcare professionals around the world. It reaches over 50 markets via direct sales and distributors. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. AngioDynamics has operating facilities in Europe, the US, Asia, and Latin America.

Company Headquarters: Vaulx-en-Velin, France Founded: 1979 Workforce: ~ 500 Company Working: EDAP TMS is a pioneer and a market leader in Extracorporeal ShockWave Lithotripsy (ESWL) with the Sonolith range of devices. Its products are marketed through a network of subsidiaries and distribution partners around the globe. It is investing in R&D heavily to maintain and strengthen its level of innovation and research. It also offers three HIFU products such as the Ablatherm, Ablatherm Fusion, and Focal One. Products including lasers, micro-ultrasound equipment, and other medical supplies are sold by its distribution division to support its international activities. The company has operations in France, the US, and other regions.

Company Headquarters: Germany Founded: 1946 Workforce: ~ 1,959 Company Working: Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. Biotest AG develops, manufactures, and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies. Barcelona-based Grifols, a global leader in plasma-derived medicines, today announced the completion of the acquisition of Biotest AG, a European healthcare company specialized in innovative hematology and clinical immunology.

Company Headquarters: Italy Founded: 2000 Workforce: ~1,050 Company Working: Kedrion S.p.A. develops and distributes plasma-derived medicinal products. The Company produces plasma-derived products for use in treating serious diseases, disorders, and conditions such as hemophilia and immune system deficiencies. Kedrion serves customers worldwide. Kedrion is a biopharmaceutical company that specializes in the development, production, and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders, and conditions such as immune system deficiencies and coagulation disorders. The company operates through a fully integrated business model from the collection of plasma in its own centres in the United States to fractionation and production in its manufacturing facilities located in Italy, Hungary, and North America. Headquartered in Castelvecchio Pascoli (Lucca, Italy), Kedrion has approximately 2,800 employees and a commercial presence in 100 countries worldwide.

Company Headquarters: Spain Founded: 1909 Workforce: ~ 4,763 Company Working: Grifols Therapeutics, Inc. operates as a biotherapeutic and biotechnology company. The Company discovers, develops, and produces critical care treatment products for the people with life-threatening disorders. Grifols Therapeutics serves patients, hospitals, pharmacies, and healthcare professionals worldwide. Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing, and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies. Grifols' plasma fractionation capacity is 3.6 million liters of plasma a year and is carried out in the company's two plants located in Parets del Valles (Barcelona) and Los Angeles.

Company Headquarters: UK, Europe Founded: 2012 Workforce: ~ 500 Company Working: Exscientia is a global pharma tech company using patient-first AI, drug discovery, and design enterprise. The company offers its products under the category of the precision target, precision design, precision experiment, and precision medicine. Moreover, the company platform has delivered the first three AI-system to improve clinical outcome in oncology. The company has strong business presence in Europe region.

Company Headquarters: US Founded: 1911 Workforce: ~2,88,300 Company Working: International Business Machines Corporation (IBM) is a technology company. The Company segments include Cloud & Cognitive Software, Global Business Services (GBS), Systems and Global Financing. The Cloud & Cognitive Software Solutions segment delivers integrated and secure cloud, data and artificial intelligence (AI) solutions to its clients. It comprises three business areas: cognitive applications, cloud & data platforms, and transaction processing platforms. The GBS segment provides consulting, business process and application management services. The Global Financing segment is engaged in financing, which is primarily conducted through IBM Credit LLC, and remanufacturing and remarketing. The Systems segment provides clients with infrastructure platforms to help meet the requirements of hybrid multi-cloud and enterprise AI workloads. It also provides telco consulting services and solutions to help communications service providers (CSP) and media on multiple cloud platforms. Geographically, the company classifies its operations into three segments, namely, the Americas, Europe, the Middle East & Africa, and Asia-Pacific.

Health Catalyst, Inc. is a healthcare data-and-analytics technology and services company headquartered in the Salt Lake City metropolitan area. It was incorporated in Delaware in September 2011 under the name HQC Holdings, Inc., and adopted its current name in March 2017, though the operating business traces to 2008 — a lineage the current CEO references directly, describing "eighteen years working with health systems" on the Q2 2026 earnings call (Q2 2026 earnings release, 6 Aug 2026). The company completed its initial public offering in July 2019. **Positioning statement (150 words).** Health Catalyst occupies the healthcare-specific layer of the provider data stack: it ingests, normalises and governs clinical, claims, financial and operational data for health systems, then sells analytics applications and human expertise on top of it. Its distinctive asset is not infrastructure — management now openly concedes the data-platform layer has commoditised against Databricks, Snowflake and Microsoft — but a proprietary corpus of measured improvement outcomes accumulated over 18 years and more than 2,000 documented, client-verified improvements. The 2026 strategy under new CEO Ben Albert reframes the company as a "healthcare intelligence" business: an AI-enabled improvement layer that quantifies, prioritises and sequences cost, clinical-quality, ambulatory-growth and consumer interventions. Execution risk is acute. The company is simultaneously migrating clients off its legacy DOS platform, restructuring its cost base, having divested its most profitable software unit, and carrying an accumulated deficit above USD 1.5 billion against a market capitalisation near USD 135 million. --- ### 2.1 The company's own description The FY2025 Form 10-K opens with an unchanged framing: *"We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data and analytics platform, software applications, and expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. We envision a future where all healthcare decisions are data-informed."* The company organises its self-description around three components: (i) the Ignite Data & Analytics Platform, a healthcare-specific, cloud-based, open and self-service ecosystem for analytics, application development and interoperability; (ii) Applications, software analytics products built on Ignite across five focus areas — Clinical Improvement, Revenue & Cost Improvement, Ambulatory Operations, Measures & Registries, and Data & Analytics; and (iii) Expertise, a services organisation of data engineers, data scientists, clinicians and healthcare administrators delivering implementation, analytics, abstraction, cost-accounting and Tech-Enabled Managed Services (TEMS). The company describes its operating philosophy through the "Health Catalyst Flywheel": team-member engagement drives quality of work, which drives measurable client improvement, which drives client trust, renewal, expansion and referral, which drives predictable financial performance. This construct is not decorative — it is referenced in the executive compensation design disclosed in the 10-K/A, where annual bonus outcomes for all team members are tied to client outcomes, growth and Adjusted EBITDA. By August 2026 the company's boilerplate had been rewritten materially. The Q2 2026 release describes Health Catalyst as *"a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance,"* backed by *"deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes."* The shift from "data and analytics technology and services" to "healthcare intelligence" is the clearest single marker of the strategy reset. ### 2.2 Independent characterisation Health Catalyst is, in economic terms, a hybrid of three businesses that have historically been bundled and are now being deliberately unbundled. The first is a healthcare data-platform business (formerly DOS, now Ignite) sold on multi-year subscription. This is the anchor relationship: it creates switching costs, it is the surface on which applications are sold, and it is the layer under most competitive pressure. Management's Q1 2026 admission that "healthcare data infrastructure has increasingly commoditized" is a significant concession from a company whose original thesis was that healthcare data warehousing required purpose-built architecture. The second is a portfolio of point-solution applications, largely assembled through twelve acquisitions since 2018 — patient engagement (Twistle, Upfront), care orchestration (Lumeon), oncology (Carevive), registries (ARMUS, CRStar/ERS), measures (MeasureAble/Able Health), cost accounting (PowerCosting), labour management (PowerLabor), interoperability (Ninja Universe/KPI Ninja), cybersecurity (Intraprise), and — until 31 July 2026 — mid-revenue-cycle (Vitalware). These applications carry higher gross margins than services and are the intended vehicle for AI monetisation. The third is a professional services and managed-services organisation. This is the structurally problematic segment: FY2025 adjusted gross margin of 18.3% and GAAP gross margin of 12.8%, on revenue that declined 8% year over year. Management now guides this business to roughly USD 55 million annually exiting 2026, versus USD 111.7 million in FY2024 — a deliberate contraction of nearly half. **Revenue model mix.** The company reports two revenue lines only: Technology revenue is predominantly recurring subscription; professional services is a mix of recurring managed services (TEMS) and project-based, non-recurring engagement revenue. The company explicitly flags fluctuation in "project-based, non-recurring revenue" as a principal risk in every earnings release reviewed. **Value-chain position.** Health Catalyst sits between the EHR system of record (Epic, Oracle Health) and the health system's executive decision-making layer. It does not own the transactional workflow; it owns the analytic abstraction of it. This is simultaneously its defensibility (EHR vendors historically underinvested in cross-source analytics) and its vulnerability (EHR vendors are now investing heavily, and the 10-K names "the increasing market share of EHR companies in data analytic services, patient engagement and other parts of our Solution" as a specific cause of contract termination risk). **Customer types and end-markets.** Academic medical centres, integrated delivery networks, community hospitals, large physician practices, Accountable Care Organizations, health information exchanges, health insurers, life-science organisations, healthcare technology vendors (for cybersecurity) and other risk-bearing entities. Named clients in the FY2025 10-K: Allina Health, AlohaCare, Baylor Scott & White Health, Carle Health, Children's Hospital of Orange County, Community Health Network, Contexture, INTEGRIS Health, Lifepoint Health, Mass General Brigham, MultiCare, Queen's Health System, Temple University Health System, UnityPoint Health, UPMC. No client represented more than 10% of total revenue in FY2025, FY2024 or FY2023 (10-K FY2025). ---

Company Headquarters: New York, US Founded: 1999 Workforce: ~40,000 Company Working: ExlService Holdings Inc (ExlService) is a business process management service provider. The company offers domain expertise, operations management, data analytics, digital technology platforms, and various services such as insurance, healthcare, and banking solutions. It also provides financial, travel, transportation, and logistics solutions, finance and accounting solutions, consulting services, analytics solutions, and digital solutions. It serves the insurance, healthcare, travel and leisure, transportation and logistics, banking and financial, and utility industries. It has a business presence in the US, Europe, Latin America, South Africa, Australia, and Asia.

Company Headquarters: Illinois, US ‎ Founded: 1986 Workforce: ~8,400 Company Working: Allscripts Healthcare, LLC (Allscripts) is a leader in healthcare information technology solutions, providing advanced clinical, financial, and operational results to clients. The company offers comprehensive healthcare industry solutions designed to help clients improve the quality and efficiency of healthcare services by providing electronic health records (EHR), financial management, population health management, and precise medicine/consumer solutions. The company has a global presence across 7 countries: the US, Australia, India, Canada, Singapore, Israel, and the UK.

Symrise AG is one of the four global majors in flavors and fragrances (F&F), alongside Givaudan, dsm-firmenich and IFF, and the only one headquartered in Germany. Its distinctiveness lies in breadth beyond classic F&F: through the 2014 Diana acquisition it built the world's leading pet food palatability franchise, and through its Cosmetic Ingredients (now "Care & Wellness") and Aroma Molecules businesses it supplies cosmetic actives, UV filters, menthol and specialty aroma chemicals in which it is backward-integrated. The group generated €4.93 bn of sales in FY2025 with a decade-high adjusted EBITDA margin of 21.9% and record business free cash flow of €780 m. Under CEO Jean-Yves Parisot, the "ONE Symrise" strategy rests on three pillars — growth, efficiency and portfolio management — and is executed through the "ONE SYM" transformation programme. The 2025–2028 ambition is 5–7% organic sales CAGR, a 21–23% EBITDA margin and a business free cash flow margin above 14%. --- **Company self-description.** Symrise describes itself as a global supplier of fragrances and flavors, cosmetic active ingredients and raw materials, as well as functional ingredients. Its customers include perfume, cosmetics, food and beverage manufacturers, the pharmaceutical industry and producers of dietary supplements and pet food (Symrise boilerplate, Q1 2026 release, 29 April 2026). **Independent characterisation.** Symrise is a B2B ingredient and solution formulator that sits in the middle of the consumer-goods value chain. Upstream, it sources several thousand raw materials — agricultural naturals (vanilla from Madagascar, citrus, onion, botanicals), animal by-products (for pet palatants and proteins), petrochemical and terpene-derived intermediates — and converts them into proprietary compositions (flavor and fragrance formulas) or standalone ingredients (aroma molecules, cosmetic actives, UV filters, menthol, pet protein). Downstream, it sells to consumer packaged goods companies (food, beverage, home and personal care, fine fragrance houses), pet food manufacturers, and supplement/pharma companies. **Business model.** The core F&F model is a "brief-win" model: customers issue briefs for new or reformulated products; Symrise competes (often on a core-list basis with a limited number of approved suppliers) to have its formula selected. Once a formula is embedded in a customer's product, it typically generates recurring volume for the product's lifecycle because reformulation is costly and risky for the customer. This creates annuity-like revenue with high switching costs. Formulas are protected chiefly as trade secrets rather than patents. **Revenue model mix.** Essentially 100% product revenue. Symrise does not report material service, subscription or licensing revenue. Revenue is a function of customer volumes multiplied by price, with price pass-through mechanisms for raw-material inflation (typically with a lag of two to three quarters). The FY2025 and 2026 commentary shows the sensitivity: Q1 2026 organic decline of 0.4% comprised +0.3% volume and −0.7% price (Q1 2026 call). **Value-chain position.** Symrise is more backward-integrated than most peers: it produces its own aroma molecules (menthol, terpene derivatives until the 2026 AmeriTerpenes sale), operates a vanilla supply chain in Madagascar, and in pet food it collects and processes animal by-products at plants near customer facilities. This integration supports supply security and margins but adds capital intensity. **Customer types.** Multinational CPG companies (global key accounts), regional and local food and beverage manufacturers (an important growth driver in emerging markets), fine fragrance houses, pet food manufacturers, cosmetics brands, and nutraceutical/probiotic customers. **End-markets served.**

Company Headquarters: Illinois, United States Founded: 1902 Workforce: ~42,000 Company Working: Archer-Daniels-Midland Company (ADM) is one of the leading manufacturers and suppliers of various food & beverage ingredients and agricultural products. The product portfolio of the company comprises diversified products ranging from natural flavors and colors to vegetable oil, sweeteners to flour, animal feed, and biofuels among others catering to human nutrition, animal nutrition, pet nutrition, and industrial bio solutions industry. Ag services and oilseeds, carbohydrate solutions, and nutrition are the three business operating segments. The Ag services and oilseeds segment is dedicated to the operations and processing of agricultural raw materials and oilseeds which are marketed as ingredients for other industrial production. The Carbohydrate Solutions segment markets various sweeteners and other ingredients for animal feed manufacturing and the food & beverage industry. Apart from its production, the company has around half of the equity interest share in a sweeteners and starch company, Aston Foods and Food Ingredients, Russia. The nutrition segment comprises the production of hydrocolloids, emulsifiers, natural colors, polyols, enzymes, prebiotics & probiotics, plant-based proteins, and several other similar specialty ingredients. The company is also involved in the Investment and Insurance business through ADM Investors Services, Inc., Agri national Insurance companies, and allied subsidiaries. The company executes its production and research & development through different plants, and innovative centers located in different regions including eight innovation centers, twenty-five processing plants, and fifty-nine procurement centers in Asia-Pacific. Further, it has five innovation centers, thirty-nine processing plants, and sixty-nine procurement centers in South America.

Company Headquarters: US Founded: 1996 Workforce: ~11,300 Company Working: Tupperware is a leading manufacturer of premium and innovative product offerings. Its product range comprises customer-oriented storage and serving solutions focused on kitchenware and other domestic applications that mainly comprise food storage, serving & preparation, containers, and toys & gifts. The company operates in more than 80 countries across Europe, the Middle East & Africa, Asia-Pacific, North America, and South America. Tupperware has about 2,000 distributors, 113,200 managers (comprising directors and team leaders), and 2.9 million sales team members across the globe.